75225-50-2

Basic information

• Product Name: Lovastatin sodium salt
• Synonyms: Lovastatin Hydroxy Acid;Lovastatin EP IMpurity B;MB 530B;LOVASTATIN HYDROXY ACID, SODIUM SALT;LOVASTATIN SODIUM;LOVASTATIN SODIUM SALT;[1s-[1a(bs,ds),2a,6b,8b(r),8aa]]-1,2,6,7,8,8a-hexahydro-b,d-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic acid monosodium salt;sodium mevinolinate
• CAS NO: 75225-50-2
• Molecular Formula: C₂₄H₃₇O₆*Na
• Molecular Weight: 444.54
• Product Categories: Intermediates & Fine Chemicals;Metabolites;Pharmaceuticals
• Mol File: 75225-50-2.mol
• Article Data: 3

Chemical Properties

• Melting Point: 154-160°C
• Boiling Point: 602.3°C at 760 mmHg
• Flash Point: 199.1°C
• Appearance: /
• Vapor Pressure: 5.09E-17mmHg at 25°C
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• Stability: Hygroscopic
• CAS DataBase Reference: Lovastatin sodium salt(CAS DataBase Reference)
• NIST Chemistry Reference: Lovastatin sodium salt(75225-50-2)
• EPA Substance Registry System: Lovastatin sodium salt(75225-50-2)

Safety Data

• Hazardous Substances Data: 75225-50-2(Hazardous Substances Data)

Usage

Chemical Properties

White Powder

Uses

Different sources of media describe the Uses of 75225-50-2 differently. You can refer to the following data:
1. A metabolite of Lovastatin
2. Brimonidine Intermediate
3. Lovastatin Hydroxy Acid, Sodium Salt (Lovastatin EP Impurity B) is a metabolite of Lovastatin.

InChI:InChI=1/C24H38O6.Na/c1-5-15(3)24(29)30-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-18(25)12-19(26)13-22(27)28;/h6-7,10,14-16,18-21,23,25-26H,5,8-9,11-13H2,1-4H3,(H,27,28);/q;+1/p-1/t14-,15-,16-,18+,19+,20-,21-,23-;/m0./s1

Upstream product

• 75330-75-5 lovastatin 

Relevant articles and documents

PROCESSES FOR PREPARING AMINE SALTS OF SILDENAFIL-ANALOGUES AND USE THEREOF

A series of amine salts including a structure of formula (I) and formula (III) have provided. In formula I or formula (III), R1, Ra and RX are as defined in the specification. The amine complex salts disclosed in the present inventio

HDL-boosting combination therapy complexes

A pharmaceutical composition including therapeutically effective amounts of at least one HMG-CoA reductase inibitor present as a dyhydroxyacid salt and at least one additional therapeutic agent.